{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:19:38Z","timestamp":1788542378453,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T00:00:00Z","timestamp":1445644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tuberculosis (TB) could be fatal if left untreated, however, adverse effects of anti-TB medications (anti-TBs) themselves may limit treatment. We determined the incidence and clinical characteristics of hepatotoxicity in hospitalized patients receiving first-line anti-TB treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study of patients aged \u226518 years seen at the medical wards of the Jos University Teaching Hospital from January 2013 to June 2013 was carried out. Data were retrieved for 110 patients who were prescribed anti-TBs. Their demographic and clinical characteristics were described, and the incidence of symptomatic hepatotoxicity determined. The incidence of hepatotoxicity by strict American Thoracic Society criteria (symptomatic hepatotoxicity plus alanine transaminase in IU\/L levels &gt;3\u00d7upper limit of normal) was also determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty patients developed symptomatic hepatotoxicity, giving an incidence of 18.2%. Furthermore, 18 (16.4%) patients had hepatotoxicity according to the American Thoracic Society criteria. Those with symptomatic hepatotoxicity unexpectedly had lower baseline alanine transaminase interquartile range (IQR) (35 [16\u201363] vs. 67 [4\u2013226];\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =.04) and bilirubin (\u03bcmol\/L): total IQR (15.3 [10.2\u201374.8] vs. 20.4 [20.4\u201320.4];\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =.01) and conjugated IQR (7.6 [5.1\u201334.8] vs. 10.2 [10.2\u201310.2];\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      =.004). However, there were no significant differences in age, sex, body mass index, and duration of anti-TB treatment, human immunodeficiency virus infection status, antiretroviral therapy status, alcohol consumption, and the presence of hepatitis B surface antigen or hepatitis C virus antibody.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Hepatotoxicity due to first-line anti-TBs, whether based on clinical features alone or backed by liver chemistry, is common among hospitalized patients in our environment. Studies to determine the predictors of hepatotoxicity to guide clinical interventions aimed at the prevention or timely identification of cases are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijmyco.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T20:19:58Z","timestamp":1446581998000},"page":"21-26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria"],"prefix":"10.4103","volume":"5","author":[{"given":"Samson E.","family":"Isa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine O.","family":"Ebonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan Y.","family":"Shehu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Idoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Anejo-Okopi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gomerep","family":"Simji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael U.","family":"Odesanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac O.","family":"Abah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsat O.","family":"Jimoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-4-20260904","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/thx.45.5.403","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Committee of the British Thoracic Society","volume":"45","author":"Ormerod","year":"1990","journal-title":"Thorax"},{"key":"R4-4-20260904","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.puhe.2004.05.012","article-title":"The trend of pulmonary tuberculosis in patients seen at DOTS clinics in the Federal Capital Territory, Abuja, Nigeria","volume":"119","author":"Bassey","year":"2005","journal-title":"Public Health"},{"key":"R5-4-20260904","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-todate review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J. Gastroenterol. Hepatol"},{"key":"R6-4-20260904","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drugrelated liver dysfunction in chronic hepatitis B infection","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"R7-4-20260904","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Anti-TB drug-induced hepatotoxicity. The role of hepatitis C and the HIV","volume":"157","author":"Ungo","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"R8-4-20260904","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from anti-TB drugs: a case-control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"R9-4-20260904","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis druginduced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"},{"key":"R10-4-20260904","first-page":"1978","article-title":"Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients","volume":"90","author":"Ozick","year":"1995","journal-title":"Am. J. Gastroenterol"},{"key":"R11-4-20260904","first-page":"683","article-title":"Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population","volume":"8","author":"Gross","year":"1999","journal-title":"Cancer Epidemiol. Biomarkers Prev"},{"key":"R13-4-20260904","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Jussi","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"R14-4-20260904","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-008-9085-y","article-title":"Prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases","volume":"2","author":"Makhlouf","year":"2008","journal-title":"Hepatol. Int"},{"key":"R15-4-20260904","doi-asserted-by":"crossref","first-page":"e1809","DOI":"10.1371\/journal.pone.0001809","article-title":"Anti-tuberculosis drug induced hepatotoxicity among TB\/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested casecontrol study","volume":"3","author":"Hassen","year":"2008","journal-title":"PLoS One"},{"key":"R16-4-20260904","first-page":"710","article-title":"The clinical characteristics of anti-tuberculosis drug induced liver injury in 2457 hospitalized patients with tuberculosis in China","volume":"7","author":"An","year":"2013","journal-title":"Afr. J. Pharm. Pharmacol"},{"key":"R17-4-20260904","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1345\/aph.1D525","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors","volume":"38","author":"Shakya","year":"2004","journal-title":"Ann. Pharmacother"},{"key":"R18-4-20260904","doi-asserted-by":"crossref","first-page":"e85905","DOI":"10.1371\/journal.pone.0085905","article-title":"The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1","volume":"9","author":"Xiang","year":"2014","journal-title":"PLoS One"},{"key":"R19-4-20260904","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"key":"R20-4-20260904","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4038\/cmj.v51i1.1369","article-title":"Antituberculosis drug induced hepatitis \u2013 a Sri Lankan experience","volume":"51","author":"Senaratne","year":"2006","journal-title":"Ceylon Med. J"},{"key":"R21-4-20260904","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2004.10.009","article-title":"Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during anti-TB treatment","volume":"51","author":"Sharifzadeh","year":"2005","journal-title":"Pharmacol. Res"},{"key":"R22-4-20260904","first-page":"65","article-title":"The management of antituberculosis drug-induced hepatotoxicity","volume":"5","author":"Tahaoglu","year":"2001","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R23-4-20260904","first-page":"1499","article-title":"The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity","volume":"8","author":"Fernandez-Villar","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R24-4-20260904","first-page":"1226","article-title":"Antituberculosis druginduced hepatitis: risk factors, prevention and management","volume":"41","author":"Hussain","year":"2003","journal-title":"Indian J. Exp. Biol"},{"key":"R25-4-20260904","first-page":"163","article-title":"Antituberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome","volume":"17","author":"Khalili","year":"2009","journal-title":"DARU"},{"key":"R26-4-20260904","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1258\/ijsa.2008.008361","article-title":"Adverse events to anti- TB therapy: influence of HIV and antiretroviral drugs","volume":"20","author":"Marks","year":"2009","journal-title":"Int. J. STD AIDS"},{"key":"R27-4-20260904","first-page":"78","article-title":"Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-TB treatment","volume":"11","author":"Pukenyte","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R28-4-20260904","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general program conditions in Singapore","volume":"6","author":"Teleman","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"R29-4-20260904","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/01926230252824699","article-title":"Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity","volume":"30","author":"Williams","year":"2002","journal-title":"Toxicol. Pathol"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553115001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S2212553115001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01929415-201605010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:01:28Z","timestamp":1788541288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01929415-201605010-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijmyco.2015.10.001","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}